Phase 0 approaches, including microdosing, involve the use of sub-therapeutic exposures to the tested drugs, thus enabling safer, more-relevant, quicker and cheaper first-in-human (FIH) testing. These approaches also have considerable potential to limit the use of animals in human drug development. Recent years have witnessed progress in applications, methodology, operations, and drug development culture. Advances in applications saw an expansion in therapeutic areas, developmental scenarios and scientific objectives, in, for example, protein drug development and paediatric drug development. In the operational area, the increased sensitivity of Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS), expansion of the utility of Positron Emission Tomography (PET) imaging, and the introduction of Cavity Ring-Down Spectroscopy (CRDS), have led to the increased accessibility and utility of Phase 0 approaches, while reducing costs and exposure to radioactivity. PET has extended the application of microdosing, from its use as a predominant tool to record pharmacokinetics, to a method for recording target expression and target engagement, as well as cellular and tissue responses. Advances in methodology include adaptive Phase 0/Phase 1 designs, cassette and cocktail microdosing, and Intra-Target Microdosing (ITM), as well as novel modelling opportunities and simulations. Importantly, these methodologies increase the predictive power of extrapolation from microdose to therapeutic level exposures. However, possibly the most challenging domain in which progress has been made, is the culture of drug development. One of the main potential values of Phase 0 approaches is the opportunity to terminate development early, thus not only applying the principle of ‘kill-early-kill-cheap’ to enhance the efficiency of drug development, but also obviating the need for the full package of animal testing required for therapeutic level Phase 1 studies. Finally, we list developmental scenarios that utilised Phase 0 approaches in novel drug development.
MunosB. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery8, 959–968.
2.
PaulS.M., MytelkaD.S., DunwiddieC.T., PersingerC.C., MunosB.H., LindborgS.R., & SchachtA.L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery9, 203–214.
3.
FDA (2004). Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products.Silver Spring, MD, USA: Food and Drug Administration. Available at: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html (Accessed 13.12.18).
4.
DiMasiJ.A., GrabowskiH.G., & HansenR.W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics47, 20–33.
5.
ScannellJ.W., BlanckleyA., BoldonH., & WarringtonB. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery11, 191–200.
6.
BurtT., YoshidaK., LappinG., VuongL., JohnC., de WildtS.N., SugiyamaY., & RowlandM. (2016). Microdosing and other Phase-0 clinical trials: Facilitating translation in drug development. Clinical & Translational Science9, 74–88.
7.
ICH (2009). Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals M3(R2). In International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, pp. 8–16. Geneva, Switzerland: ICH Secretariat.
8.
FDA (2006). Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies, 13 pp. Silver Spring, MD, USA: Food and Drug Administration.
9.
LappinG., & GarnerR.C. (2003). Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nature Reviews Drug Discovery2, 233–240.
10.
SugiyamaY. (2009). Effective use of microdosing and Positron Emission Tomography (PET) studies on new drug discovery and development. Drug Metabolism & Pharmacokinetics24, 127–129.
11.
BergstromM., GrahnenA., & LangstromB. (2003). Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. European Journal of Clinical Pharmacology59, 357–366.
12.
MarshallL.J., AustinC.P., CaseyW., FitzpatrickS.C., & WillettC. (2018). Recommendations toward a human pathway-based approach to disease research. Drug Discovery Today23, 1824–1832.
13.
BurtT., & CombesR.D. (2018). The use of imaging, biomonitoring and microdosing in human volunteers to improve safety assessments and clinical development. In The History of Alternative Test Methods in Toxicology (ed. BallsM., CombesR., & WorthA.), pp. 229–240. New York, NY, USA: Elsevier/ Academic Press.
14.
VuongL.T., SongQ., LeeH.J., RoffelA.F., ShinS-H., ShinY.G., & DuekerS.R. (2015). Opportunities in low-level radiocarbon microtracing: Applications and new technology. Future Science OA2, 1–22.
15.
WagnerC.C., MullerM., LappinG., & LangerO. (2008). Positron emission tomography for use in microdosing studies. Current Opinion in Drug Discovery & Development11, 104–110.
16.
MaedaK., & SugiyamaY. (2011). Novel strategies for microdose studies using non-radiolabeled compounds. Advanced Drug Delivery Reviews63, 532–538.
17.
LappinG., NoveckR., & BurtT. (2013). Microdosing and drug development: Past, present and future. Expert Opinion on Drug Metabolism & Toxicology9, 817–834.
18.
RowlandM., & BenetL.Z. (2011). Lead PK commentary: Predicting human pharmacokinetics. Journal of Pharmaceutical Sciences100, 4047–4049.
19.
LappinG., KuhnzW., JochemsenR., KneerJ., ChaudharyA., OosterhuisB., DrijfhoutW.J., RowlandM., & GarnerR.C. (2006). Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs. Clinical Pharmacology & Therapeutics80, 203–215.
20.
PoulinP., JonesR.D., JonesH.M., GibsonC.R., RowlandM., ChienJ.Y., RingB.J., AdkisonK.K., KuM.S., HeH., VuppugallaR., MaratheP., FischerV., DuttaS., SinhaV.K., BjörnssonT., LavéT., & YatesJ.W. (2011). PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. Journal of Pharmaceutical Sciences100, 4127–4157.
21.
BurtT., NoveckR.J., MacLeodD.B., LaytonA.T., RowlandM., & LappinG. (2017). Intra-Target Microdosing (ITM): A novel drug development approach aimed at enabling safer and earlier translation of biological insights into human testing. Clinical & Translational Science10, 337–350.
22.
BurtT., MacLeodD., LeeK., SantoroA., DeMasiD.K., HawkT., FeinglosM., RowlandM., & NoveckR.J. (2017). Intra-target microdosing — A novel drug development approach: Proof of concept, safety, and feasibility study in humans. Clinical & Translational Science10, 351–359.
23.
BurtT., JohnC.S., RuckleJ.L., & VuongL.T. (2016). Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: A range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans — a practical guide. Expert Opinion on Drug Delivery14, 657–672.
24.
KusuharaH., TakashimaT., FujiiH., TakashimaT., TanakaM., IshiiA., TazawaS., TakahashiK., TakahashiK., TokaiH., YanoT., KataokaM., InanoA., YoshidaS., HosoyaT., SugiyamaY., YamashitaS., HojoT., & WatanabeY. (2017). Comparison of pharmacokinetics of newly discovered aromatase inhibitors by a cassette microdosing approach in healthy Japanese subjects. Drug Metabolism & Pharmacokinetics32, 293–300.
25.
BauerM., LangerO., Dal-BiancoP., KarchR., BrunnerM., AbrahimA., LanzenbergerR., HofmannA., JoukhadarC., CarminatiP., GhirardiO., PiovesanP., ForloniG., CorradoM.E., LodsN., DudczakR., AuffE., KletterK., & MüllerM. (2006). A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clinical Pharmacology & Therapeutics80, 216–227.
26.
LappinG., WarringtonS., HoneybourneD., SangheraD., DowenS., ListerN., IslamK., & LociuroS. (2007). Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. [Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA].
27.
KaplanN., GarnerC., & HafkinB. (2013). AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. European Journal of Pharmaceutical Sciences50, 440–446.
28.
JohnstromP., BergmanL., VarnasK., MalmquistJ., HalldinC., & FardeL. (2015). Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nuclear Medicine & Biology42, 555–560.
29.
StephensM.L., & MakN.S. (2013). History of the 3Rs in toxicity testing: From Russell and Burch to 21st century toxicology. In Reducing, Refining and Replacing the Use of Animals in Toxicity Testing (ed. AllenD., & WatersM.J.), pp. 1–43. Cam bridge, UK: Royal Society of Chemistry.
30.
FDA (2017). FDA's Predictive Toxicology Roadmap, 13 pp. Silver Spring, MD, USA: Food and Drug Administration.
31.
NIH (2018). A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemical and Medical Products in the United States, 12 pp. Washington, DC, USA: Interagency Coordinating Committee on the Validation of Alternative Methods.
32.
RowlandM. (2012). Microdosing: A critical assessment of human data. Journal of Pharmaceutical Sciences101, 4067–4074.
33.
ShaddyR.E., & DenneS.C. (2010). Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics125, 850–860.
34.
CuzzolinL., AtzeiA., & FanosV. (2006). Off-label and unlicensed prescribing for newborns and children in different settings: A review of the literature and a consideration about drug safety. Expert Opinion on Drug Safety5, 703–718.
35.
GoreR., ChughP.K., TripathiC.D., LhamoY., & GautamS. (2017). Pediatric off-label and unlicensed drug use and its implications. Current Clinical Pharmacology12, 18–25.
36.
KimlandE., & OdlindV. (2012). Off-label drug use in pediatric patients. Clinical Pharmacology & Therapeutics91, 796–801.
37.
DunneJ., RodriguezW.J., MurphyM.D., BeasleyB.N., BurckartG.J., FilieJ.D., LewisL.L., SachsH.C., SheridanP.H., StarkeP., & YaoL.P. (2011). Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics128, e1242–e1249.
38.
BellisJ.R., KirkhamJ.J., ThiesenS., ConroyE.J., BrackenL.E., MannixH.L., BirdK.A., DuncanJ.C., PeakM., TurnerM.A., SmythR.L., NunnA.J., & PirmohamedM. (2013). Adverse drug reactions and off-label and unlicensed medicines in children: A nested case-control study of inpatients in a pediatric hospital. BMC Medicine11, 238.
39.
MomperJ.D., MulugetaY., & BurckartG.J. (2015). Failed pediatric drug development trials. Clinical Pharmacology & Therapeutics98, 245–251.
40.
AllegaertK., & van den AnkerJ. (2015). Neonatal drug therapy: The first frontier of therapeutics for children. Clinical Pharmacology & Therapeutics98, 288–297.
41.
Roth-ClineM., & NelsonR.M. (2015). Microdosing studies in children: A US regulatory perspective. Clinical Pharmacology & Therapeutics98, 232–233.
42.
ZimmerL. (2008). Can positron emission tomography facilitate paediatric drug development?Fundamental & Clinical Pharmacology, 22, 595–598.
43.
TurnerM.A., MooijM.G., VaesW., WindhorstA.D., HendrikseN.H., KnibbeC.A., KõrgveeL.T., MaruszakW., GrynkiewiczG., GarnerR.C., TibboelD., ParkB.K., & de WildtS.N. (2015). Pediatric microdose and microtracer studies using 14C in Europe. Clinical Pharmacology & Therapeutics98, 234–237.
44.
MooijM.G., van DuijnE., KnibbeC.A., AllegaertK., WindhorstA.D., van RosmalenJ., HendrikseN.H., TibboelD., VaesW.H.J., & de WildtS.N. (2017). Successful use of [14C]paracetamol micro-dosing to elucidate developmental changes in drug metabolism. Clinical Pharmacokinetics56, 1185–1195.
45.
Roth-ClineM., & NelsonR.M. (2015). Ethical considerations in conducting pediatric and neonatal research in clinical pharmacology. Current Pharmaceutical Design21, 5619–5635.
46.
VuongL.T., BloodA.B., VogelJ.S., AndersonM.E., & GoldsteinB. (2012). Applications of accelerator MS in pediatric drug evaluation. Bioanalysis4, 1871–1882.
47.
MorganP., van der GraafP.H., ArrowsmithJ., FeltnerD.E., DrummondK.S., WegnerC.D., & StreetS.D. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today17, 419–424.
48.
TurteltaubK.W., FeltonJ.S., GledhillB.L., VogelJ.S., SouthonJ.R., CaffeeM.W., FinkelR.C., NelsonD.E., ProctorI.D., & DavisJ.C. (1990). Accelerator mass spectrometry in biomedical dosimetry: Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proceedings of National Academy of Sciences of the USA87, 5288–5292.
DuekerS.R., VuongL.T., LohstrohP.N., GiacomoJ.A., & VogelJ.S. (2011). Quantifying exploratory low dose compounds in humans with AMS. Advanced Drug Delivery Reviews63, 518–531.
51.
McCarttA.D., OgnibeneT.J., BenchG., & TurteltaubK.W. (2016). Quantifying carbon-14 for biology using cavity ring-down spectroscopy. Analytical Chemistry88, 8714–8719.
52.
GalliI., BartaliniS., BalleriniR., BarucciM., CancioP., de PasM., GiusfrediG., MazzottiD., AkikusaN., & de NataleP. (2016). Spectroscopic detection of radiocarbon dioxide at parts-per-quadrillion sensitivity. Optica3, 385–388.
53.
FleisherA.J., LongD.A., LiuQ., GamesonL., & HodgesJ.T. (2017). Optical measurement of radiocarbon below unity fraction modern by linear absorption spectroscopy. Journal of Physical Chemistry Letters8, 4550–4556.
54.
KratochwilN.A., DuekerS.R., MuriD., SennC., YoonH., YuB.Y., LeeG.H., DongF., & OttenederM.B. (2018). Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies. PLoS One13, e0205435.
55.
SugiyamaY., & YamashitaS. (2011). Impact of microdosing clinical study — Why necessary and how useful?Advanced Drug Delivery Reviews, 63, 494–502.
56.
IeiriI., TsunemitsuS., MaedaK., AndoY., IzumiN., KimuraM., YamaneN., OkuzonoT., MorishitaM., KotaniN., KandaE., DeguchiM., MatsugumaK., MatsukiS., HirotaT., IrieS., KusuharaH., & SugiyamaY. (2013). Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. Journal of Clinical Pharmacology53, 654–661.
57.
ShingakiT., TakashimaT., IjuinR., ZhangX., OnoueT., KatayamaY., OkauchiT., HayashinakaE., CuiY., WadaY., SuzukiM., MaedaK., KusuharaH., SugiyamaY., & WatanabeY. (2013). Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats. Journal of Pharmacology & Experimental Therapeutics347, 193–202.
58.
MaedaK., IkedaY., FujitaT., YoshidaK., AzumaY., HaruyamaY., YamaneN., KumagaiY., & SugiyamaY. (2011). Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clinical Pharmacology & Therapeutics90, 575–581.
59.
WagnerJ., DahlemA.M., HudsonL.D., TerryS.F., AltmanR.B., GillilandC.T., DeFeoC., & AustinC.P. (2018). A dynamic map for learning, communicating, navigating and improving therapeutic development. Nature Reviews Drug Discovery17, 150.
60.
DiMasiJ.A., HansenR.W., & GrabowskiH.G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics22, 151–185.
61.
MadanA., O'BrienZ., WenJ., O'BrienC., FarberR.H., BeatonG., CroweP., OosterhuisB., GarnerR.C., LappinG., & BozigianH.P. (2008). A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. British Journal of Clinical Pharmacology67, 288–298.
62.
CarpenterA.P.Jr., PontecorvoM.J., HeftiF.F., & SkovronskyD.M. (2009). The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: A review of one company's experience. Quarterly Journal of Nuclear Medicine & Molecular Imaging53, 387–393.
63.
WangJ.L., AstonK., LimburgD., LudwigC., HallinanA.E., KoszykF., HamperB., BrownD., GranetoM., TalleyJ., MaziaszT., MasferrerJ., & CarterJ. (2010). The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates. Bioorganic & Medicinal Chemistry Letters20, 7164–7168.
64.
OkourM., DerimanovG., BarnettR., FernandezE., FerrerS., GreshamS., HossainM., GamoF.J., KohG., PereiraA., RolfeK., WongD., YoungG., RamiH., & HaseldenJ. (2018). A human microdose study of the anti-malarial GSK3191607 in healthy volunteers. British Journal of Clinical Pharmacology84, 482–489.
65.
VlamingM., van DuijnE., DillinghM.R., BrandsR., WindhorstA.D., HendrikseN.H., BosgraS., BurggraafJ., de KoningM.C., FidderA., MockingJ.A., SandmanH., de LigtR.A., FabriekB.O., PasmanW.J., SeinenW., AlvesT., CarrondoM., PeixotoC., PeetersP.A., & VaesW.H. (2015). Microdosing of a carbon-14 labeled protein in healthy volunteers accurately predicts its pharmacokinetics at therapeutic dosages. Clinical Pharmacology & Therapeutics98, 196–204.
66.
MooijM.G., van DuijnE., KnibbeC.A., WindhorstA.D., HendrikseN.H., VaesW.H., SpaansE., FabriekB.O., SandmanH., GrossouwD., HanffL.M., JanssenP.J., KochB.C., TibboelD., & de WildtS.N. (2014). Pediatric microdose study of [14C]paracetamol to study drug metabolism using accelerated mass spectrometry: Proof of concept. Clinical Pharmacokinetics53, 1045–1051.
67.
BalC., AroraG., KumarP., DamleN., DasT., ChakrabortyS., BanerjeeS., VenkateshM., ZaknunJ.J., & PillaiM.R. (2016). Pharmacokinetic, dosimetry and toxicity study of 177Lu-EDTMP in patients: Phase 0/I study. Current Radiopharmaceuticals9, 71–84.
68.
KummarS., KindersR., GutierrezM.E., RubinsteinL., ParchmentR.E., PhillipsL.R., JiJ., MonksA., LowJ.A., ChenA., MurgoA.J., CollinsJ., SteinbergS.M., EliopoulosH., GirandaV.L., GordonG., HelmanL., WiltroutR., Tomas zewskiJ.E., & DoroshowJ.H. (2009). Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of Clinical Oncology27, 2705–2711.
69.
HeuvelingD.A., de BreeR., VugtsD.J., HuismanM.C., GiovannoniL., HoekstraO.S., LeemansC.R., NeriD., & van DongenG.A. (2013). Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. Journal of Nuclear Medicine54, 397–401.
SmithD., CombesR., DepelchinO., JacobsenS.D., HackR., LuftJ., LammensL., von LandenbergF., PhillipsB., PfisterR., RabemampianinaY., SparrowS., StarkC., & Stephan-GueldnerM. (2005). Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog. Regulatory Toxicology & Pharmacology41, 95–101.
72.
SmithD., CombesR., DescotesG., JacobsenS.D., HackR., KemkowskiJ., KrauserK., LammensL., PfisterR., PhillipsB., RabemampianinaY., SparrowS., Stephan-GueldnerM., & von LandenbergF. (2003). 167. Approaches to the minimisation of dog use in the safety assessment of pharmaceuticals: An industry/animal welfare initiative [Conference Abstract]. Toxicology Letters144, Suppl. 1, s48.
73.
CombesR., BallsM., IllingP., BhogalN., DaleJ., DuvéG., FeronV., GrindonC., GüldenM., LoizouG., PristonR., & WestmorelandC; FRAME (2006). Possibilities for a new approach to chemicals risk assessment — The report of a FRAME workshop. ATLA34, 621–649.
74.
CombesR. (2013). Progress in the development, validation and regulatory acceptance of in vitro methods for toxicity testing. In Elsevier Reference Module in Chemistry, Molecular Sciences and Chemical Engineering (ed. ReedijkJ.), pp. 1–25. Waltham, MA, USA: Elsevier.
75.
BéruBéK., AufderheideM., BrehenyD., ClothierR., CombesR., DuffinR., ForbesB., GaçaM., GrayA., HallI., KellyM., LethemM., LiebschM., MerollaL., MorinJ.P., SeagraveJ., SwartzM.A., TetleyT.D., & UmachandranM. (2009). In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. ATLA37, 89–141.
76.
BaileyJ., ThewM., & BallsM. (2014). An analysis of the use of animal models in predicting human toxicology and drug safety. ATLA42, 181–199.
